Menu
Fechar
hrs4r
Quiero donar

DAVID GALLARDO GIRALT

Hematología
Firma
DAVID GALLARDO-GIRALT
Posición
Cap de Grup - R4
Jefe de Grupo - R4
Projectes
Publicacions

Projectes

Hematología

Genotipo de las moléculas inhibidoras de respuesta inmune: más allá del trasplante alogénico. Banco nacional de ADN de pacientes tratados con terapia CAR-T.

Codi oficial: PI20/01353 Data inicio:01/01/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III
Hematología

Relevancia del genotipo de LAG3 y moléculas checkpoint en el trasplante alogénico de progenitores hematopyéticos.

Codi oficial: Projecte IJC - Dr. David Gallardo Data inicio:01/07/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS
Hematología

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Hematologia

Codi oficial: 6822ZB3KJ Data inicio:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA

Publicacions

Nihtilä J, Salmenniemi U, Itälä-Remes M, Crossland RE, Gallardo D, Bogunia-Kubik K, Lacina P, Bieniaszewska M, Giebel S, Hyvärinen K, Kekäläinen E, Ritari J, Partanen J

Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort

HUMAN IMMUNOLOGY, 2024, 85, 110791-110791 dx.doi.org/10.1016/j.humimm.2024.110791
Gonzalez-Montes, Y, Osca-Gelis, G, Rodriguez-Romanos, R, Villavicencio, A, González-Bártulos, M, Llopis, F, Clapes, V, Oriol, A, Sureda, A, Escoda, L, Sarrà, J, Garzó, A, Lloveras, N, Gómez, B, Granada, I, Gallardo, D

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2024, 15, 1252445-1252445 dx.doi.org/10.3389/fimmu.2024.1252445
Nihtilä J, Penna L, Salmenniemi U, Itälä-Remes M, Crossland RE, Gallardo D, Bogunia-Kubik K, Lacina P, Bieniaszewska M, Giebel S, Karjalainen K, Jahan F, Kerkelä E, Hyvärinen K, Koskela S, Ritari J, Partanen J

Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity.

SCIENTIFIC REPORTS, 2024, 14, 26988-26988 dx.doi.org/10.1038/s41598-024-78619-5
Sanchez, JLP, Ljungman, P, Kulagin, A, Stanghellini, MTL, Solano, C, Tridello, G, Mayer, J, Suarez-Lled , M, Labussi re-Wallet, H, Zeiser, R, Clay, J, Sandstedt, AB, Heras, I, Kalwak, K, Lopez, JL, Schaffrath, J, Balduzzi, A, Benedetti, F, Hayat, A, Gallardo, D, Koene, H, Rif n, J, Schlegel, PG, Knelange, N, Averbuch, D, De la Camara, R

SARS-COV-2 CYCLE THRESHOLD LEVELS AND COVID-19 OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION. AN INFECTIOUS DISEASE WORKING PARTY STUDY

BONE MARROW TRANSPLANTATION, 2024, 59, 441-442
Tammi, S, Nihtila, J, Koskela, S, Hyvarinen, K, Salmenniemi, U, Itala-Remes, M, Crossland, RE, Gallardo, D, Bogunia-Kubik, K, Lacina, P, Bieniaszewska, M, Giebel, S, Partanen, J, Ritari, J

IMPACT OF MIC AND NON-CLASSICAL HLA-E, -F AND -G ALLELES AND THEIR MISMATCHING TOGETHER WITH CLINICAL DATA ON ALLO-HSCT COMPLICATIONS

BONE MARROW TRANSPLANTATION, 2024, 59, 771-771
Nihtil , J, Salmenniemi, U, It l -Remes, M, Crossland, RE, Gallardo, D, Bogunia-Kubik, K, Lacina, P, Bieniaszewska, M, Giebel, S, Koskela, S, Hyv rinen, K, Partanen, J, Ritari, J

WHOLE GENOME MATCHING ANALYSIS FOR GRAFT-VERSUS-HOST DISEASE AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

BONE MARROW TRANSPLANTATION, 2024, 59, 768-768
Oliveira AC, Roncero JM, Ferrá C, Do Nascimento J, Rodriguez-Luaces M, Encuentra M, Domingo-Domenech E, López P, Gallardo D, Ribera JM, Sarrá J, Sureda A, González-Barca E

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117, 388-397 dx.doi.org/10.1007/s12185-022-03488-5
Cruz D, Rodríguez-Romanos R, González-Bartulos M, García-Cadenas I, de la Cámara R, Heras I, Buño I, Santos N, Lloveras N, Velarde P, Tuset E, Martínez C, González M, Sanz GF, Ferrá C, Sampol A, Coll R, Pérez-Simón JA, López-Jiménez J, Jurado M, Gallardo D

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

Frontiers in Immunology, 2023, 14, 1066393-1066393 dx.doi.org/10.3389/fimmu.2023.1066393
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105
Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, Queipo DE Llano MP, Coll R, Gallardo D, Vall-Llovera F, Escoda L, García-Guiñon A, Salamero O, Sampol A, Merchan B, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Blood Advances, 2022, 6, 1193-1206 dx.doi.org/10.1182/bloodadvances.2021005585

Formulari de contacte

Conoce el IDIBGI!

 menu